Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): consensus on obesity and cardiometabolic comorbidities in inflammatory bowel disease using systematic reviews and the RAND/UCLA appropriateness method Authors: Jalpa Devi, Sami Samaan, Priya Sehgal, Mouhand Mohamed, Matthew Vincent, Shannon Coombs, Michelle Doering, Edward L Barnes, Amanda M Johnson, Andres J Yarur, Parakkal Deepak Published: 2026 ABSTRACT Abstract AbstractIntroductionObesity and related cardiometabolic comorbidities, including hypertension, dyslipidaemia, diabetes, metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease, are increasingly prevalent among individuals with inflammatory bowel disease (IBD). These conditions influence disease activity, therapeutic response, surgical outcomes and overall quality of life, yet evidence remains fragmented. The Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD) initiative aims to synthesise evidence and generate consensus recommendations to guide practice and future research in this area. This study describes a protocol for a structured evidence synthesis and Research ANd Development/University of California, Los Angeles (RAND/UCLA) Appropriateness Method (RUAM) consensus process.Methods and analysisWe will conduct three systematic reviews and a structured evidence synthesis organised into three domains: (1) the impact of obesity on IBD outcomes, (2) the burden of cardiometabolic complications in IBD and (3) the management of overweight, obesity and cardiometabolic comorbidities in IBD. A multidisciplinary international panel of gastroenterologists, surgeons, endocrinologists, hepatologists, cardiologists and dietitians will assess each statement using the RAND/UCLA appropriateness method. Panellists will rate the appropriateness of each statement (only those that fall within their area of expertise) on a 1–9 scale (1–3=inappropriate, 4–6=uncertain and 7–9=appropriate), with medians rounded up (eg, 6.5=appropriate). Agreement will be assessed using the RAND Disagreement Index (DI<1.0=agreement).Ethics and disseminationThis study will not involve direct patient participation, as it is based on evidence synthesis and expert consensus; therefore, formal research ethics committee approval will not be required. Patient representatives will contribute to the consensus process to provide contextual perspectives but no identifiable data will be collected.Findings will be disseminated through publication in peer-reviewed journals, presentation at major gastroenterology and IBD conferences and communication with professional societies. A lay summary and patient-friendly infographic will also be developed to facilitate translation of recommendations into clinical practice.PROSPERO registration numbersCRD420251178843: a systematic review of the impact of obesity on inflammatory bowel disease outcomes.CRD420251178799: a systematic review of cardiometabolic complications in inflammatory bowel disease.CRD420251174653: management of overweight, obesity and cardiometabolic comorbidities in inflammatory bowel disease: a systematic review.Keywords: Obesity, Bariatric Surgery, Inflammatory bowel disease, Body Mass Index, Inflammation STRENGTHS AND LIMITATIONS OF THIS STUDY Integrates systematic evidence synthesis with RAND/UCLA methods, an approach not previously applied to obesity and cardiometabolic comorbidities in inflammatory bowel disease. Integrates systematic evidence synthesis with RAND/UCLA methods, an approach not previously applied to obesity and cardiometabolic comorbidities in inflammatory bowel disease. An international, multidisciplinary panel (gastroenterology, surgery, endocrinology, cardiology, dietitians and radiology) ensures broad expertise. An international, multidisciplinary panel (gastroenterology, surgery, endocrinology, cardiology, dietitians and radiology) ensures broad expertise. Anonymous scoring and iterative re-rating reduce bias while enabling structured discussion. Anonymous scoring and iterative re-rating reduce bias while enabling structured discussion. Patient and public involvement will inform priorities and dissemination, although RAND scoring remains expert-only. Patient and public involvement will inform priorities and dissemination, although RAND scoring remains expert-only. Evidence is largely observational and rapidly evolving (eg, glucagon-like peptide-1 receptor agonists and endobariatric therapies), necessitating future updates. Evidence is largely observational and rapidly evolving (eg, glucagon-like peptide-1 receptor agonists and endobariatric therapies), necessitating future updates. Introduction Obesity and cardiometabolic comorbidities are increasingly recognised as important modifiers of disease course and outcomes in inflammatory bowel diseases (IBD). Recent epidemiological studies estimate that 12%–40% of adults with IBD are obese, with an additional 25%-40% qualifying as overweight.1 2 The prevalence of metabolic syndrome approaches 19%, with even higher rates seen in ulcerative colitis (UC) than Crohn’s disease (CD), and risks of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are elevated compared with the general population.3,7 Obesity is linked to more active and relapsing disease, greater need for hospitalisation and increased extraintestinal manifestations.8 9 Therapeutic response is attenuated in patients with IBD and obesity, particularly to biologics and immunomodulators, due to altered drug pharmacokinetics and lower trough levels, resulting in reduced rates of steroid-free remission.10 11 Surgical outcomes are also negatively affected, with higher perioperative complication rates, longer hospital stays and greater healthcare costs, risks that are most pronounced with excess visceral adiposity.12 13 Beyond medical and surgical outcomes, obesity and cardiometabolic complications are associated with impaired quality of life, including higher levels of fatigue, anxiety, depression and pain.9 14 Moreover, the rapid expansion of anti-obesity therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), bariatric surgery and bariatric endoscopy, has outpaced the development of IBD-specific guidance.15 16 The lack of harmonised definitions and recommendations has led to fragmented care, with variability in practice across regions and specialties. As such, there is an urgent need for a rigorous, evidence-based and expert-driven consensus to guide clinical care and new discovery. Accordingly, this manuscript outlines the protocol for the evidence synthesis and consensus development process. Aims and objectives The primary objective of the Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD) initiative is to develop evidence-based consensus recommendations for the management of obesity and cardiometabolic comorbidities in patients with IBD, informed by systematic review (SR) and RAND/UCLA expert consensus methodology. Secondary objectives include: To define and standardise the assessment of obesity and cardiometabolic comorbidities in IBD (eg, body mass index (BMI), visceral adipose tissue (VAT), body composition, metabolic syndrome and MASLD). To define and standardise the assessment of obesity and cardiometabolic comorbidities in IBD (eg, body mass index (BMI), visceral adipose tissue (VAT), body composition, metabolic syndrome and MASLD). To evaluate the impact of obesity and metabolic syndrome on medical and surgical outcomes in IBD, including response to biologics, treatment durability, postoperative complications and disease recurrence. To evaluate the impact of obesity and metabolic syndrome on medical and surgical outcomes in IBD, including response to biologics, treatment durability, postoperative complications and disease recurrence. To provide guidance on the role and impact of lifestyle interventions, pharmacotherapy, bariatric surgery and bariatric endoscopy in the management of patients with IBD and obesity. To provide guidance on the role and impact of lifestyle interventions, pharmacotherapy, bariatric surgery and bariatric endoscopy in the management of patients with IBD and obesity. To highlight gaps in evidence and set research priorities for future clinical trials and translational studies. To highlight gaps in evidence and set research priorities for future clinical trials and translational studies. Clinical domains Three domains with subtopics will structure the review and consensus process across three work groups: Domain 1: the impact of obesity on IBD outcomes. Obesity and disease activity, severity and natural history. Obesity and disease activity, severity and natural history. Obesity and response to medical therapy. Obesity and response to medical therapy. Obesity and surgical outcomes in IBD. Obesity and surgical outcomes in IBD. Obesity, body composition and inflammatory biomarkers. Obesity, body composition and inflammatory biomarkers. Differential effects by IBD subtype and adiposity phenotype. Differential effects by IBD subtype and adiposity phenotype. Domain 2: cardiometabolic complications in IBD. Epidemiology of cardiometabolic comorbidities in IBD. Epidemiology of cardiometabolic comorbidities in IBD. MASLD/MASH (metabolic dysfunction-associated steatohepatitis) and its complications in IBD. MASLD/MASH (metabolic dysfunction-associated steatohepatitis) and its complications in IBD. CVD and major adverse cardiovascular events in IBD. CVD and major adverse cardiovascular events in IBD. Metabolic syndrome, diabetes, hypertension and dyslipidaemia in IBD. Metabolic syndrome, diabetes, hypertension and dyslipidaemia in IBD. Impact of cardiometabolic complications on IBD-related outcomes. Impact of cardiometabolic complications on IBD-related outcomes. Domain 3: management of overweight, obesity and cardiometabolic comorbidities in IBD. Measures and definitions of obesity and visceral adiposity in IBD. Measures and definitions of obesity and visceral adiposity in IBD. Lifestyle interventions (dietary modifications, physical activity and behavioural interventions). Lifestyle interventions (dietary modifications, physical activity and behavioural interventions). Pharmacologic management.Anti-obesity therapies (including GLP-1RAs).Antidiabetic, antihypertensive and lipid-lowering therapies. Pharmacologic management. Anti-obesity therapies (including GLP-1RAs). Anti-obesity therapies (including GLP-1RAs). Antidiabetic, antihypertensive and lipid-lowering therapies. Antidiabetic, antihypertensive and lipid-lowering therapies. Multidisciplinary care models and preventive strategies. Multidisciplinary care models and preventive strategies. Bariatric and endobariatric procedures in IBD. Bariatric and endobariatric procedures in IBD. Methods and analysis Study design and registration This consensus project will integrate systematic evidence synthesis and RAND/UCLA expert consensus. The three SRs are registered with PROSPERO (CRD420251174653, CRD420251178799 and CRD420251178843). Timeline Start date: 1 September 2025. Start date: 1 September 2025. Completion date: 30 November 2026. Completion date: 30 November 2026. Part 1: SR Study selection and search strategy The evidence review will be conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered with PROSPERO. A comprehensive search of MEDLINE, Embase, Web of Science and the Cochrane Library (from January 1991 to 2 September 2025) will be undertaken, supplemented with clinical trial registries (ClinicalTrials.gov, EU CTR, ISRCTN and WHO ICTRP) and grey literature. These registries were selected as they represent the major international trial registries with broad coverage across regions and study types; additional registries were not included due to substantial overlap and limited incremental yield. Search strategies will use controlled vocabulary and free-text terms for IBD, obesity, overweight, weight management, cardiometabolic conditions and relevant interventions (lifestyle, pharmacologic, surgical and endobariatric). Inclusion and exclusion criteria will be applied to identify observational and interventional studies in adults with IBD. The search will be limited to studies published in English due to feasibility constraints, including resource limitations for translation and data extraction; however, this may introduce language bias. Eligibility criteria, including study design, population and intervention characteristics, are detailed in online supplemental appendix 1. Data extraction Two independent reviewers will screen titles and abstracts in Covidence (Veritas Health Innovation) for each of the three workgroups. Screening and data extraction will be performed independently by two reviewers within each SR, with discrepancies resolved through discussion with a designated third reviewer. For SR1 (management of obesity and cardiometabolic comorbidities in IBD), reviewers will be JD and SS, with MV as the third reviewer; for SR2 (cardiometabolic complications in IBD), reviewers will be MV and SC, with PS as the third reviewer and for SR3 (impact of obesity on IBD outcomes), reviewers will be PS and MM, with JD as the third reviewer. A predefined extraction form will capture study design, population characteristics, interventions, comparators, outcomes and adverse events. For pharmacotherapy, dose and duration will be recorded; for lifestyle interventions, type, frequency and intensity and for surgical approaches, procedure type and perioperative details. Disease-related outcomes will include, but are not limited to, disease activity, clinical and endoscopic remission (including steroid-free remission), hospitalisation, need for surgery, treatment escalation and inflammatory biomarkers (eg, C-reactive protein and faecal calprotectin). Findings will be reviewed and finalised by the principal investigator group (AMJ, PD and AJY) to ensure consistency, methodological rigour and oversight across all workstreams. Risk-of-bias (quality) assessment Risk of bias will be assessed independently by two reviewers. The Cochrane Risk of Bias 2 tool will be used for randomised controlled trials and risk of bias in non-randomised studies of interventions (ROBINS-I) for observational studies. Methodological quality will be tabulated, and any disagreements will be adjudicated by consensus. Strategy for data synthesis Heterogeneity in study design and outcome measures is anticipated. Where feasible, random-effects meta-analysis will be performed, reporting mean differences (continuous outcomes) or risk ratios/ORs (dichotomous outcomes) with 95% CIs. Statistical heterogeneity will be assessed using the I² statistic. When meta-analysis is not feasible, a structured narrative synthesis will be provided. Where meta-analysis is feasible, sensitivity analyses will be performed to assess the robustness of findings and publication bias will be evaluated using funnel plots and/or Egger’s test where appropriate. Analysis of subgroups or subsets Planned subgroup analyses include IBD subtype (CD vs UC), BMI category (overweight vs obese), intervention type (lifestyle, pharmacotherapy, psychotherapy, surgical and endobariatric), cardiometabolic comorbidity type (eg, diabetes, MASLD and atherosclerotic CVD (ASCVD)) and concomitant IBD therapies (biologic vs non-biologic). Part 2: consensus development process Selection and recruitment of stakeholders A multidisciplinary expert panel (target n=50–60) will be convened, including gastroenterologists, colorectal surgeons, bariatric surgeons, endobariatric endoscopists, endocrinologists, hepatologists, cardiologists, radiologists, dietitians and pharmacists. This panel size is consistent with prior RAND/UCLA consensus studies and is intended to ensure adequate multidisciplinary and geographic representation while maintaining feasibility and meaningful group interaction. Experts will be identified through structured searches of faculty profiles, bibliometric analyses of obesity-IBD publications and professional society networks (International Organisation for the Study of Inflammatory Bowel Disease, European Crohn’s and Colitis Organisation, American Gastroenterological Association, American College of Gastroenterology and Asian Pacific Association of Gastroenterology). Invitations will be distributed via personalised email from the study lead, detailing study aims, RAND/UCLA process and expected time commitment (~20–30 min per round). Eligibility will require demonstrable clinical or research expertise in obesity, metabolic disease or IBD, with attention to gender, geographic and career-stage diversity. Participation will be voluntary with electronic consent, and panellists will receive acknowledgement under MODIFY-IBD authorship. Engagement will be promoted through reminder emails and feedback summaries after each round. Those unable to complete a round will be invited to participate in subsequent rounds to mitigate attrition bias (figure 1). Workflow of the MODIFY-IBD evidence synthesis and consensus development process. IBD, inflammatory bowel disease; MODIFY-IBD, Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes; PICO, population, intervention, comparator and outcome; RAND/University of California Los Angeles appropriateness method (RUAM); SR1, systematic review 1; SR2, systematic review 2; SR3, systematic review 3. Rounds description Round 1: independent online scoring of draft statements. Round 1: independent online scoring of draft statements. Round 2: structured discussion of statements with disagreement or uncertainty in a virtual interim meeting, followed by re-rating. Round 2: structured discussion of statements with disagreement or uncertainty in a virtual interim meeting, followed by re-rating. Round 3: final rating if consensus not achieved in Round 2. Round 3: final rating if consensus not achieved in Round 2. Data management Data collected through each survey round will be analysed in aggregate by the study investigators. Washington University in St Louis will serve as the data custodian, with the lead investigator (PD) responsible for ensuring compliance with institutional privacy and data security standards. All data will be stored on encrypted, access-restricted institutional servers (eg, Qualtrics) and will be accessible only to the core research team. No identifiable information will be shared outside the study team. De-identified datasets and summary statistics will be archived for 5 years, following study completion in accordance with institutional policy. Definitions Obesity will be defined primarily as BMI≥30 kg/m², with additional body composition metrics (waist circumference, VAT and sarcopenia indices) included where available. Cardiometabolic comorbidities include hypertension, dyslipidaemia, T2DM, metabolic syndrome (National Cholesterol Education Program-Adult Treatment Panel III/International Diabetes Federation), ASCVD and MASLD/MASH. Survey generation Draft statements will be derived from the SR evidence summaries and structured into the Population, Intervention, Comparator and Outcome format where possible. Each statement will undergo pilot testing by 10 members of the study management group, representing diverse clinical and methodological expertise, to assess clarity, content validity and feasibility. Feedback from this pilot phase will be used to refine wording, structure and survey flow before distribution to the full expert panel. Given the paucity of robust data, we will use the RAND/UCLA appropriateness method (RUAM), which combines systematic evidence appraisal with expert judgement to generate clinically relevant recommendations. Statements will be organised into predefined clinical domains and presented in a structured, domain-based format to preserve clinical coherence and facilitate expert interpretation. Content validity will be ensured through multidisciplinary expert review and alignment with the underlying SR evidence. Panellists will also have the opportunity to provide free-text feedback during each round, allowing iterative refinement of statements across the RAND/UCLA process. RUAM To systematically determine the appropriateness of key clinical statements, we will employ the RUAM, a validated and widely used modified Delphi technique.17 This method integrates the best available evidence with expert clinical judgement to assess the balance of benefits and harms for each proposed statement, particularly when randomised trial data are limited or absent.18 The RUAM has demonstrated strong reliability, internal consistency and clinical validity across a range of medical and surgical disciplines, including IBD.19,23 Each statement will be rated for appropriateness on a 1–9 scale (1–3=inappropriate, 4–6=uncertain and 7–9=appropriate). Median scores will be calculated and rounded up; for example, a median of 3.5 will be classified as uncertain, while a median of 6.5 will be rated as appropriate. Final appropriateness ratings will be based on median scores of 7, 8 or 9. Equation DI = (66th percentile−33rd percentile)/[2.35+1.5×((66th percentile+33rd percentile)/2)]. The measure of agreement will be determined using the RAND DI, which incorporates the spread between the 33rd and 66th percentiles. A DI≥1.0 indicates disagreement (extreme variation), whereas a DI<1.0 reflects general agreement. Ratings will be conducted in Qualtrics. Median, IQR and percentage agreement will be calculated per item. Indicators rated 7–9 by ≥50% of participants in Round 1 will advance to Round 2. Consensus will be defined as a median of 7–9 and RAND DI<1.0; change in ratings between rounds will be assessed using the Wilcoxon signed-rank test. Data analysis For each statement, we will report the median, IQR and percentage agreement to describe the level of consensus. Changes in ratings between rounds will be assessed using the Wilcoxon signed-rank test. If response bias is suspected, subgroup analyses by specialty or region will be performed. Free-text responses will be collected to capture the rationale underlying extreme ratings (scores 1–3 or 7–9) and areas of disagreement. These responses will be reviewed descriptively by the study team to inform interpretation of results and iterative refinement of statements across rounds. In subsequent rounds, participants will receive anonymised feedback comparing their scores with group summaries to support reflection and re-rating. Definition of study completion The study will be considered complete once the final consensus meeting and last round of re-rating are concluded. At this stage, no new data will be collected, and results will be synthesised into recommendations. Patient and public involvement Patient representatives will be embedded within the MODIFY-IBD study management group to ensure outcomes remain relevant, accessible and patient-centred. While patients will not directly participate in the RAND/UCLA rating process due to the technical nature of the questions, they will help guide project priorities, provide feedback on statement wording and co-develop dissemination materials tailored for the wider IBD community. Rigour and limitations As with all consensus studies, potential biases may affect validity and reliability.24 We will reduce selection bias by applying predefined eligibility criteria and ensuring multidisciplinary, geographically diverse representation rather than relying solely on personal networks.25 To limit attrition, surveys will be restricted to two to three rounds with reminders.26 Anonymised scoring after group discussion will help prevent groupthink.27 Transparent reporting, protocol registration and iterative feedback from panellists will ensure methodological rigour and reproducibility.24 Ethics and dissemination Risks and consent No foreseeable risks are expected for participants. Informed electronic consent will be obtained through a mandatory initial survey question prior to participation in the rating process. Panellists may withdraw at any time without consequence. Confidentiality Responses will be anonymised and linked to unique IDs. Only aggregated data will be shared for group feedback, and all files will be stored on a secure, institution-approved server of Qualtrics at Washington University in St Louis, accessible to the study team. Ethics approval As this study involves evidence synthesis and expert consensus without personal data, formal ethics board approval is not required. Dissemination Results will be shared through peer-reviewed publications, conference presentations and summaries for professional societies and patient groups. A lay infographic and open-access supplementary materials will accompany the final publication. Discussion This study describes a protocol that will generate a structured, evidence-based framework to guide the management of obesity and related cardiometabolic comorbidities in patients with IBD. By combining systematic evidence synthesis with the RUAM, the MODIFY-IBD initiative will provide a measurable, consensus-driven set of statements to inform clinical decision-making, determine research priorities and support guideline development. Limitations While the consensus process is grounded in published data, certain knowledge gaps remain due to limited high-quality studies specific to IBD populations. Much of the available evidence is derived from observational studies, which are subject to residual confounding and limit causal inference. In addition, substantial heterogeneity exists across studies in terms of definitions of obesity, body composition measures and outcome reporting, which may affect the comparability of findings. For example, evidence guiding optimal use of GLP-1 RAs, endobariatric procedures and multidisciplinary care pathways in IBD is still evolving. Similarly, real-world data on long-term cardiometabolic outcomes, such as major adverse cardiovascular events or MASLD progression, are sparse. These limitations highlight the importance of expert input and transparent reporting of uncertainty through RAND/UCLA methodology. Because expert panels are composed of clinicians, researchers and patient representatives from multiple specialties and regions, some variation in interpretation is expected. Furthermore, the RAND/UCLA method incorporates expert opinion, which may introduce selection bias and variability in interpretation. Attrition across survey rounds may also introduce response bias, although this will be mitigated through structured engagement strategies. Publication and reporting bias cannot be excluded, particularly given the rapidly evolving literature in this field. However, using structured rating rounds, anonymised scoring and iterative feedback will mitigate bias and enhance reproducibility. Finally, the generalisability of findings may vary across healthcare systems and practice settings, particularly where access to multidisciplinary care and advanced therapies differs. Ultimately, this work seeks to establish common definitions, treatment paradigms and evidence-to-decision frameworks that will support high-quality, multidisciplinary care for patients with obesity and IBD. The resulting statements will also inform the design of future clinical trials, quality improvement initiatives and implementation studies focused on cardiometabolic risk reduction in IBD. Progress to date Preparatory work, including literature searches, PROSPERO registrations and initial panel invitations, was completed between September and November 2025. The first round of surveys is planned for early 2026, followed by iterative analysis and a virtual consensus meeting later that year. Supplementary material Footnotes Funding: PD is supported by a Litwin grant and IBD Plexus of the Crohn’s and Colitis Foundation, the Helmsley Charitable Trust, the Leo and Carean Goss Crohn’s Disease Research Fund and Washington University (WU) DDRCC (NIDDK P30 DK052574). Prepub: Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-115709). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details. References Supplementary Materials